

Highlights of This Issue 2275

SPECIAL FEATURES

CCR Translations

- 2277 | **PRAMEing a Picture of Differentiation Therapy for AML?**

Robert L. Redner
See article, p. 2562

- 2280 | **Classifying MMR Variants: Time for Revised Nomenclature in Lynch Syndrome**

Y. Nancy You and Eduardo Vilar
See article, p. 2432

CCR New Strategies

- 2283 | **New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers**

Yuri E. Nikiforov, Linwah Yip, and Marina N. Nikiforova

CCR Perspectives in Drug Approval

- 2289 | **U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma**

Michael Axelson, Ke Liu, Xiaoping Jiang, Kun He, Jian Wang, Hong Zhao, Dubravka Kufirin, Todd Palmby, Zedong Dong, Anne Marie Russell, Sarah Miksinski, Patricia Keegan, and Richard Pazdur

Molecular Pathways

- 2294 | **Molecular Pathways: Radiation-Induced Cognitive Impairment**

Dana Greene-Schloesser, Elizabeth Moore, and Mike E. Robbins

- 2301 | **Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance**

Antonia L. Pritchard and Nicholas K. Hayward

Review

- 2310 | **Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma**



Lipika Goyal, Mandar D. Muzumdar, and Andrew X. Zhu

HUMAN CANCER BIOLOGY

- 2319 | **NIK Controls Classical and Alternative NF-κB Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells**

Lina Odqvist, Margarita Sánchez-Beato, Santiago Montes-Moreno, Esperanza Martín-Sánchez, Raquel Pajares, Lydia Sánchez-Verde, Pablo L. Ortiz-Romero, Jose Rodriguez, Socorro M. Rodríguez-Pinilla, Francisca Iniesta-Martínez, Juan Carlos Solera-Arroyo, Rafael Ramos-Asensio, Teresa Flores, Javier Menarguez Palanca, Federico García Bragado, Purificación Domínguez Franjo, and Miguel A. Piris

- 2331 | **High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition**

Elisabeth Wik, Even Birkeland, Jone Trovik, Henrica M.J. Werner, Erling A. Hoivik, Siv Mjos, Camilla Krakstad, Kanthida Kusunmano, Karen Mauland, Ingunn M. Stefansson, Frederik Holst, Kjell Petersen, Anne M. Oyan, Ronald Simon, Karl H. Kalland, William Ricketts, Lars A. Akslen, and Helga B. Salvesen

- 2342 | **PI3K/AKT Signaling Is Essential for Communication between Tissue-Infiltrating Mast Cells, Macrophages, and Epithelial Cells in Colitis-Induced Cancer**

Mohammad W. Khan, Ali Keshavarzian, Elias Gounaris, Joshua E. Melson, Eric C. Cheon, Nichole R. Blatner, Zongmin E. Chen, Fu-Nien Tsai, Goo Lee, Hyunji Ryu, Terrence A. Barrett, David J. Bentrem, Philipp Beckhove, and Khashayarsha Khazaie

CANCER THERAPY: PRECLINICAL

IMAGING, DIAGNOSIS, PROGNOSIS

- 2355 **Targeted Delivery of *microRNA-29b* by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia**
Xiaomeng Huang, Sebastian Schwind, Bo Yu, Ramasamy Santhanam, Hongyan Wang, Pia Hoellerbauer, Alice Mims, Rebecca Klisovic, Alison R. Walker, Kenneth K. Chan, William Blum, Danilo Perrotti, John C. Byrd, Clara D. Bloomfield, Michael A. Caligiuri, Robert J. Lee, Ramiro Garzon, Natarajan Muthusamy, Ly James Lee, and Guido Marcucci
- 2368 **Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma**
Christina A. von Roemeling, Laura A. Marlow, Johnny J. Wei, Simon J. Cooper, Thomas R. Caulfield, Kevin Wu, Winston W. Tan, Han W. Tun, and John A. Copland
- 2381 **Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET**
Cristina Basilio, Selma Pennacchietti, Elisa Vigna, Cristina Chiriaco, Sabrina Arena, Alberto Bardelli, Donatella Valdembri, Guido Serini, and Paolo Michieli
- 2393 **Inhibition of NF- κ B–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells**
Emilio Cosimo, Alison M. McCaig, Luke J.M. Carter-Brzezinski, Helen Wheadon, Michael T. Leach, Karine Le Ster, Christian Berthou, Emilie Durieu, Nassima Oumata, Hervé Galons, Laurent Meijer, and Alison M. Michie
- 2406 **The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF- κ B Response in Chronic Lymphocytic Leukemia Cells**
Sneha V. Gupta, Erin Hertlein, Yanhui Lu, Ellen J. Sass, Rosa Lapalombella, Timothy L. Chen, Melanie E. Davis, Jennifer A. Woyach, Amy Lehman, David Jarjoura, John C. Byrd, and David M. Lucas
- 2420 **Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease**
Suzanne E. Wardell, Erik R. Nelson, Christina A. Chao, and Donald P. McDonnell

- 2432 **Expression Defect Size among Unclassified *MLH1* Variants Determines Pathogenicity in Lynch Syndrome Diagnosis**
Inga Hinrichsen, Angela Brieger, Jörg Trojan, Stefan Zeuzem, Mef Nilbert, and Guido Plotz
See commentary, p. 2280
- 2442 **Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study**
Daniel W. Lin, Lisa F. Newcomb, Elissa C. Brown, James D. Brooks, Peter R. Carroll, Ziding Feng, Martin E. Gleave, Raymond S. Lance, Martin G. Sanda, Ian M. Thompson, John T. Wei, and Peter S. Nelson, for the Canary Prostate Active Surveillance Study Investigators
- 2451 ***PIK3CA* Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma**
Hironobu Shigaki, Yoshifumi Baba, Masayuki Watanabe, Asuka Murata, Takatsugu Ishimoto, Masaaki Iwatsuki, Shiro Iwagami, Katsuhiko Noshio, and Hideo Baba
- 2460 **Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas**
Qi Zhao, Otavia L. Caballero, Ian D. Davis, Eric Jonasch, Pheroze Tamboli, W.K. Alfred Yung, John N. Weinstein, Kenna Shaw for the TCGA research network, Robert L. Strausberg, and Jun Yao
- 2473 **Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors**
Antonella Chiechi, Chiara Novello, Giovanna Magagnoli, Emanuel F. Petricoin III, Jianghong Deng, Maria S. Benassi, Piero Picci, Iosif Vaisman, Virginia Espina, and Lance A. Liotta
- 2486 **Improved Survival with HPV among African Americans with Oropharyngeal Cancer**
Maria J. Worsham, Josena K. Stephen, Kang Mei Chen, Meredith Mahan, Vanessa Schweitzer, Shaleta Havard, and George Divine

2493 **Sequential Binary Gene Ratio Tests Define a Novel Molecular Diagnostic Strategy for Malignant Pleural Mesothelioma**

Assunta De Rienzo, William G. Richards, Beow Y. Yeap, Melissa H. Coleman, Peter E. Sugarbaker, Lucian R. Chirieac, Yaoyu E. Wang, John Quackenbush, Roderick V. Jensen, and Raphael Bueno

2503 **Tissue Redox Activity as a Hallmark of Carcinogenesis: From Early to Terminal Stages of Cancer**

Rumiana Bakalova, Zhivko Zhelev, Ichio Aoki, and Tsuneo Saga

2518 **Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101**

Thomas S.C. Ng, David Wert, Hargun Sohi, Daniel Procissi, David Colcher, Andrew A. Raubitschek, and Russell E. Jacobs

2528 **Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study**

Jong-Lyel Roh, Xin Victoria Wang, Judith Manola, David Sidransky, Arlene A. Forastiere, and Wayne M. Koch

CANCER THERAPY: CLINICAL

2541 **Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial**

Josep Tabernero, Rocio Garcia-Carbonero, James Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Irina Davidenko, Ramon Salazar, Liubov Vladimirova, Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, Irina Bulavina, Vanessa Potter, Yu-Lin Chang, Nathalie A. Lokker, and Peter J. O'Dwyer

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

2551 **Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab**

Bertrand Coiffier, Weimin Li, Erin D. Henitz, Jayaprakash D. Karkera, Reyna Favis, Dana Gaffney, Alice Shapiro, Panteli Theocharous, Yusri A. Elsayed, Helgi van de Velde, Michael E. Schaffer, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Joanna Romejko-Jarosinska, Sven de Vos, Michael Crump, Ofer Shpilberg, Pier Luigi Zinzani, Andrew Cakana, Dixie-Lee Esseltine, George Mulligan, and Deborah Ricci

2562 **PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)**

Lars Bullinger, Richard F. Schlenk, Marlies Götz, Ursula Botzenhardt, Susanne Hofmann, Annika C. Russ, Anna Babiak, Lu Zhang, Vanessa Schneider, Konstanze Döhner, Michael Schmitt, Hartmut Döhner, and Jochen Greiner
See commentary, p. 2277







2572 **FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547**


Liang Xie, Xinying Su, Lin Zhang, Xiaolu Yin, Lili Tang, Xiuhua Zhang, Yanping Xu, Zeren Gao, Kunji Liu, Minhua Zhou, Beirong Gao, Danping Shen, Lianhai Zhang, Jiafu Ji, Paul R. Gavine, Jingchuan Zhang, Elaine Kilgour, Xiaolin Zhang, and Qunsheng Ji

2584 **Characteristics of Lung Cancers Harboring NRAS Mutations**

Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila, Christine M. Lovly, Xi Chen, Charles M. Rudin, Teresa Moran, David Ross Camidge, Cindy L. Vnencak-Jones, Lynne Berry, Yumei Pan, Hidefumi Sasaki, Jeffrey A. Engelman, Edward B. Garon, Steven M. Dubinett, Wilbur A. Franklin, Gregory J. Riely, Martin L. Sos, Mark G. Kris, Dora Dias-Santagata, Marc Ladanyi, Paul A. Bunn Jr, and William Pao

ABOUT THE COVER

Assembling of microRNA-loaded transferrin-conjugated-nanoparticles to target acute myeloid leukemia (AML) blasts. The nanoparticle core was composed of negatively charged microRNA molecules (miR, ) and positively charged polyethylenimine (PEI, ). Empty nanoparticles were composed of DOPE (), linoleic acid (), and DMG-PEG (). After the loading of the PEI-miR core in the nanoparticles, transferrin-PEG-DSPE () was inserted into the nanoparticle surface for specific targeting of leukemia blasts. The background depicts a cytospin of AML blasts derived from a mouse with AML treated with miR-loaded nanoparticles. For details, see the article by Huang and colleagues on page 2355 of this issue.



AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

Clinical Cancer Research

19 (9)

Clin Cancer Res 2013;19:2275-2591.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/19/9>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/19/9>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.